AG Mednet Joins Forces with Netherlands-based CRO Cardialysis for Efficient Cardiovascular Clinical Trials
Boston, MA and Rotterdam, The Netherlands – February 26, 2014 – Speed, efficiency and accuracy are vital to the success of clinical trials. With large amounts of data collected and significant room for data submission errors, there is even greater potential to disqualify participating patients or expose subjects to unnecessary risky procedures due to data errors.
To address these needs in clinical trials, Cardialysis, an independent Clinical Research Organization (CRO), has selected AG Mednet, the leading quality compliance company as preferred provider for image data submission and collection.
With more than 30 years of experience as a full-service CRO and Core Laboratory specializing in cardiology, Cardialysis has an established network of more than 1,200 sites world-wide and works with the top pharmaceutical, medical device and biotechnology organizations globally.
“We’re responsible for designing, managing, monitoring and reporting on all aspects of clinical-research trials,” said Teun Smits, Manager Business Development at Cardialysis. “As a CRO with Core Laboratory services working with AG Mednet, we’re experiencing significant efficiencies and convenience for participating clinical sites, and as such we expect even further improvement in the quality of the data collected and transferred compared to past trials. Electronic data submission and collection contributes to our goal of becoming a fully operated eCRO. ”
AG Mednet provides the market-leading functionality and support to collect clinical trial image data globally, properly de-identify it to ensure regulatory compliance, apply advanced, automated quality-assurance processes to ensure the data is protocol-compliant and readily usable, and deliver it reliably and securely to one or more trial repositories.
“With Cardialysis, we’re working on cardiology-related studies with two major medical device companies and more than 1,000 participating patients,” said Abraham Gutman, President & CEO of AG Mednet. “We are passionate about working with organizations that are leading the industry in a positive direction and we see Cardialysis as doing exactly that. We look forward to continued collaboration with Cardialysis on future clinical trials.”
For more information about AG Mednet’s work with clinical research organizations, imaging trial sponsors, imaging core labs and principal investigators, please visit www.agmednet.com.
Cardialysis is a leading specialist clinical research organization (CRO) with an exclusive focus on cardiology, providing a full range of clinical research and cardiac Core Laboratory services. Founded in 1983, Cardialysis is recognized for its opinion-leader expertise, strong academic network and in-depth cardiology expertise and in recent years has significantly expanded its operational activities. The world’s top medical device, biotechnology and pharmaceutical companies collaborate with Cardialysis resulting in more than 250 clinical trials conducted up till now, contributing to improved cardiovascular therapies.
About AG Mednet
AG Mednet automates, expedites and improves outcomes in clinical trials by ensuring quality and compliance within critical medical imaging processes. Founded in 2005, AG Mednet is the leading quality compliance partner for image data submission and collection for pharmaceutical, biotechnology and medical device companies, imaging core labs and clinical research organizations managing clinical trials globally. More than 25,000 registered users across thousands of investigator sites in 60 countries use AG Mednet to participate in projects sponsored by each of the world’s top 20 pharmaceutical, biotech and medical device companies.
AG Mednet Media Contacts:
Dawn Sullivan or Molly Delaney